Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [¹⁷⁷Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.

ABSTRACT: Management of prostate cancer (PC) might be improved by combining external beam radiotherapy (EBRT) and prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with lutetium-177 (¹⁷⁷Lu)-labeled PSMA inhibitors. We hypothesized a higher efficacy of the combination due to augmentation of the radiation dose to the tumor and interactions of EBRT with PSMA expression potentially increasing radiopharmaceutical uptake. Therefore, this study analyzed the influence of radiation on PSMA expression levels in vitro. The results were translated to evaluate the efficacy of the combination of photon EBRT and [¹⁷⁷Lu]Lu-PSMA-617 in a murine PC xenograft model. Finally, a clinical case report on a combined elective field EBRT with RLT dose escalation illustr

SUBMITTER: Arbuznikova D 

PROVIDER: S-EPMC11024848 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature